novo nordisk oral semaglutide Company of the year 2023: – Riding the wave Ozempic and Wegovy pills now

Spending on Ozempic increased significantly between 2021 and 2022, rising from 10th to 6th place, respectively, in the top-selling Part D drugs

In a clinical trial called SUSTAIN-6, Semaglutide was shown to significantly reduce the risk of major adverse cardiovascular events, such as heart attack and stroke, in individuals with type 2 diabetes who were at high risk for cardiovascular disease

RodriguezPZhangVGratzlSDoDGoodwin CartwrightBBakerCet al

Hernandez-Cascales, J

This finding is consistent with previous literature showing that GIP secretion is inversely related to age in adults, 23 potentially due to age-related changes in insulin sensitivity or -cell responsiveness

doi: 10.1016/j.bcp.2018.07.021 67 GeislerCEAntonellisMPTrumbauerWMartinJACoskunTSammsRJet al